Comparison of Mg Vs. K Supplementation on Insomnia in Diabetics

NCT ID: NCT04642313

Last Updated: 2020-11-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

320 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-10-26

Study Completion Date

2022-04-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Insomnia is increasing alarmingly among the population. Micronutrient fluctuations have been shown to effect insulin secretion, period of circadian cycle and quality of sleep in all ages. This study is aimed to identify the impact of magnesium and potassium supplementation on insomnia severity and duration, and insulin resistance, quality of life, sleep hormones, serum magnesium and potassium levels. Moreover, the study will help to find out the link between insomnia and micronutrients among patients of diabetes mellitus so that the burden of the disease in the society could be reduced.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Sleep is the essential component to maintain good health of an individual. Insomnia is defined as a condition that affects an individual by inability to get sufficient quality sleep or problem in maintaining sleep that is important for healthy functioning, performance and well being. Insomnia can exist in healthy individual or comorbidly with other medical diseases. Latest researches indicate that intolerance of glucose in the body, resistance to insulin hormone, decreased acute response of insulin to glucose and increased chances of having type 2 diabetes are reasons for reduced or interrupted sleep. Several electrolytes and minerals influence the sleep cycle. Magnesium is important in regulation of central nervous system excitability, through ion channel conductivity. Magnesium is a muscle relaxant and inducer of the deeper sleep. Hypomagnesemia is a common feature in patients with type 2 diabetes. Although diabetes can induce hypomagnesemia, magnesium deficiency has also been proposed as a risk factor for type 2 diabetes. Magnesium supplementation improves sleep efficiency, sleep time and sleep onset latency, early morning awakening, and insomnia objective measures such as the concentration of serum renin, melatonin, and serum cortisol, in older adults. High ambient potassium levels have been shown to shorten the period of circadian rhythms in a variety of organisms. Little is known about the effects of dietary mineral nutrients on human sleep quality. Potassium depletion has been shown to cause glucose intolerance, which is associated with impaired insulin secretion . Recently, there has been growing evidence from both animal and human studies indicating that high sodium and low potassium intakes are associated with a high risk of insulin resistance or diabetes.

The Study is aimed to:

1. To compare the effect of magnesium and/ or potassium on insomnia patients with diabetes mellitus
2. To compare the gender and age based response to magnesium and/ or potassium on insomnia patients with diabetes mellitus
3. To compare the effect of magnesium and/ or potassium on insulin resistance among insomnia patients with diabetes mellitus
4. To compare the effect of magnesium and/ or potassium on sleep hormones among insomnia patients with diabetes mellitus
5. To compare the effect of magnesium and/ or potassium on serum electrolytes (Mg, K) among insomnia patients with diabetes mellitus
6. To compare the effect of magnesium and/ or potassium on quality of life (QOL) among insomnia patients with diabetes mellitus MATERIAL AND METHODS Study Design: Randomized Controlled Trial (single blind) Settings: Study will be conducted at

1\. Akhuwat Health Services, Lahore Duration of Study: 18 months (after the approval of synopsis) Sample Size: is 280 and with expected 20% drop out: 320 Sampling Technique: Non probability purposive sampling

Inclusion Criteria:

* Patients of diabetes mellitus with insomnia
* Adult diabetic patients aged between 19 to 65 years
* Patients of both genders
* Diabetic patients of insomnia with or without antidiabetic drugs

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Focus of Study is on Insomnia Among Diabetic Patients

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Insomnia, Diabetes Mellitus, Magnesium, Potassium, Melatonin, Cortisol, Insulin resistance, Quality of Life

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Participants will be divided into 4 groups and will receive 4 different treatments at same time
Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants
It will be single blind study, Participants will not be aware of the treatment group, they are receiving

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PLACEBO group

Placebo treatment: starch tablets (250 mg)

Group Type PLACEBO_COMPARATOR

Magnesium and/ or Potassium

Intervention Type OTHER

Magnesium and/ or potassium supplements will be provided to patients of diabetes mellitus with insomnia

Magnesium group

Magnesium group: Magnesium gluconate (250 mg)

Group Type EXPERIMENTAL

Magnesium and/ or Potassium

Intervention Type OTHER

Magnesium and/ or potassium supplements will be provided to patients of diabetes mellitus with insomnia

Potassium group

Potassium group: Potassium chloride (250 mg)

Group Type EXPERIMENTAL

Magnesium and/ or Potassium

Intervention Type OTHER

Magnesium and/ or potassium supplements will be provided to patients of diabetes mellitus with insomnia

Magnesium + Potassium group

Magnesium + Potassium group: Magnesium gluconate (250 mg) + Potassium chloride (250 mg)

Group Type EXPERIMENTAL

Magnesium and/ or Potassium

Intervention Type OTHER

Magnesium and/ or potassium supplements will be provided to patients of diabetes mellitus with insomnia

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Magnesium and/ or Potassium

Magnesium and/ or potassium supplements will be provided to patients of diabetes mellitus with insomnia

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* • Patients of diabetes mellitus with insomnia

* Adult diabetic patients aged between 19 to 65 years
* Patients of both genders
* Diabetic patients of insomnia with or without anti-diabetic drugs
* Diabetic patients of insomnia with or without Hypomagnesaemia
* Diabetic patients of insomnia with or without Hypokalemia

Exclusion Criteria

* Individuals with the following conditions will not be included as participants, patients of diabetes mellitus with insomnia with

* Psychiatry reasons
* Any hormonal treatment
* CVD/ Other metabolic co-morbidities
* History of acute liver injury (e.g., hepatitis) or severe cirrhosis
* Renal diseases (renal stones, renal failure, dialysis)
* Diabetic nephropathy
* Pregnancy
* Breast-feeding
* Drug induced insomnia
* Sleep disorders
* Sleep-related movement disorders (restless leg syndrome)
* Sleep-related respiratory disorders (sleep apnea)
* Alcohol consumption
* Cardiac respiratory disorders
* Painful condition (apathy)
* History of chronic liver disease
* History of CKD
* Participation in a study of an investigational medication or nutritional supplements/ medication within the past 90 days
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Lahore

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Sidra Khalid

PhD Scholar

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Akhuwat Health Services

Lahore, Punjab Province, Pakistan

Site Status RECRUITING

The University of Lahore

Lahore, Punjab Province, Pakistan

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Pakistan

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Sidra Khalid

Role: CONTACT

Phone: 0923347498338

Email: [email protected]

Shahid Bashir, PhD

Role: CONTACT

Phone: 092423200865

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Waseem Abbas, FCPS

Role: primary

Shahid Bashir, PhD

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Khalid S, Mehboob R, Bokhari SS, Ali M, Shabbir A, Mehboob K, Adnan H, Karami MM, Shalabi H, Alshehri B. Comparative Efficacy of Magnesium and Potassium Towards Cholesterol and Quality of Life in Patients With Type 2 Diabetes Mellitus: A Randomised Single-Blinded Controlled Clinical Trial. Endocrinol Diabetes Metab. 2024 Nov;7(6):e511. doi: 10.1002/edm2.511.

Reference Type DERIVED
PMID: 39410716 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UOL-UIDNS-Mg-K

Identifier Type: -

Identifier Source: org_study_id